Glanbia (GLAPY) Upgraded by Zacks Investment Research to Buy

Zacks Investment Research upgraded shares of Glanbia (OTCMKTS:GLAPY) from a hold rating to a buy rating in a report released on Tuesday. Zacks Investment Research currently has $97.00 price target on the stock.

According to Zacks, “Glanbia Plc engages in the manufacture and distribution of dairy and nutritional food products. Its operating segments include Glanbia Performance Nutrition, Global Ingredients, Dairy Ireland and Joint Ventures and Associates. Glanbia Performance Nutrition segment comprises of performance nutrition products under the Optimum Nutrition, BSN, Isopure, Nutramino and ABB brands. Global Ingredients segment includes American-style cheddar cheese, micro-nutrient premixes and dairy and non-dairy nutritional solutions. Dairy Ireland segment consists of consumer products and agribusiness. Joint Ventures and Associates segment covers Glanbia Ingredients Ireland, Glanbia Cheese and Southwest Cheese. Glanbia Plc is headquartered in Kilkenny, Ireland. “

Shares of OTCMKTS:GLAPY opened at $86.81 on Tuesday. Glanbia has a 1-year low of $80.23 and a 1-year high of $98.16.

The company also recently disclosed a Semi-Annual dividend, which was paid on Monday, October 15th. Stockholders of record on Friday, August 24th were issued a dividend of $0.531 per share. The ex-dividend date of this dividend was Thursday, August 23rd. Glanbia’s payout ratio is presently 21.03%.

About Glanbia

Glanbia plc operates as a nutrition company worldwide. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland Joint Venture. The Glanbia Performance Nutrition segment offers powders, bars and snacking food, and ready-to-drink beverages through various channels, including specialty retail, the Internet, and gyms, as well as food, drug, mass, and club channels.

See Also: What are Institutional Investors?

Get a free copy of the Zacks research report on Glanbia (GLAPY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Glanbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glanbia and related companies with's FREE daily email newsletter.

Leave a Reply